Prognostic role of genetic biomarkers in clinical progression of prostate cancer.

Alvarez-Cubero, Maria Jesus; Martinez-Gonzalez, Luis Javier; Saiz, Maria; Carmona-Saez, Pedro; Alvarez, Juan Carlos; Pascual-Geler, Manrique; Lorente, Jose Antonio; Cozar, Jose Manuel

Publication:
Prognostic role of genetic biomarkers in clinical progression of prostate cancer.

dc.contributor.author	Alvarez-Cubero, Maria Jesus
dc.contributor.author	Martinez-Gonzalez, Luis Javier
dc.contributor.author	Saiz, Maria
dc.contributor.author	Carmona-Saez, Pedro
dc.contributor.author	Alvarez, Juan Carlos
dc.contributor.author	Pascual-Geler, Manrique
dc.contributor.author	Lorente, Jose Antonio
dc.contributor.author	Cozar, Jose Manuel
dc.contributor.authoraffiliation	[Alvarez-Cubero,MJ; Saiz,M; Alvarez,JC; Lorente,JA] Laboratory of Genetic Identification, Faculty of Medicine, Legal Medicine and Toxicology Department, University of Granada, Granada, Spain. [Alvarez-Cubero,MJ; Martinez-Gonzalez,LJ; Carmona-Saez,P; Lorente,JA] GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Granada, Spain. [Pascual-Geler,M; Cozar,JM] Service of Urology, University Hospital Virgen de las Nieves, Granada, Spain.	es
dc.date.accessioned	2015-11-17T12:34:10Z
dc.date.available	2015-11-17T12:34:10Z
dc.date.issued	2015-08-07
dc.description	Journal Article;	es
dc.description.abstract	The aim of this study was to analyze the use of 12 single-nucleotide polymorphisms in genes ELAC2, RNASEL and MSR1 as biomarkers for prostate cancer (PCa) detection and progression, as well as perform a genetic classification of high-risk patients. A cohort of 451 men (235 patients and 216 controls) was studied. We calculated means of regression analysis using clinical values (stage, prostate-specific antigen, Gleason score and progression) in patients and controls at the basal stage and after a follow-up of 72 months. Significantly different allele frequencies between patients and controls were observed for rs1904577 and rs918 (MSR1 gene) and for rs17552022 and rs5030739 (ELAC2). We found evidence of increased risk for PCa in rs486907 and rs2127565 in variants AA and CC, respectively. In addition, rs627928 (TT-GT), rs486907 (AG) and rs3747531 (CG-CC) were associated with low tumor aggressiveness. Some had a weak linkage, such as rs1904577 and rs2127565, rs4792311 and rs17552022, and rs1904577 and rs918. Our study provides the proof-of-principle that some of the genetic variants (such as rs486907, rs627928 and rs2127565) in genes RNASEL, MSR1 and ELAC2 can be used as predictors of aggressiveness and progression of PCa. In the future, clinical use of these biomarkers, in combination with current ones, could potentially reduce the rate of unnecessary biopsies and specific treatments.	es
dc.description.version	Yes	es
dc.identifier.citation	Alvarez-Cubero MJ, Martinez-Gonzalez LJ, Saiz M, Carmona-Saez P, Alvarez JC, Pascual-Geler M, et al. Prognostic role of genetic biomarkers in clinical progression of prostate cancer. Exp. Mol. Med. 2015; 47:e176	es
dc.identifier.doi	10.1038/emm.2015.43
dc.identifier.essn	2092-6413
dc.identifier.issn	1226-3613
dc.identifier.pmc	PMC4558485
dc.identifier.pmid	26251261
dc.identifier.uri	http://hdl.handle.net/10668/2058
dc.journal.title	Experimental & molecular medicine
dc.language.iso	en
dc.publisher	Nature Publishing Group	es
dc.relation.publisherversion	ww.nature.com/emm/journal/v47/n8/full/emm201543a.html#abs	es
dc.rights.accessRights	open access
dc.subject	Biopsia	es
dc.subject	Estudios de seguimiento	es
dc.subject	Frecuencia de los genes	es
dc.subject	Humanos	es
dc.subject	Masculino	es
dc.subject	Clasificación del tumor	es
dc.subject	Nucleótidos	es
dc.subject	Polimorfismo de nucleótido simple	es
dc.subject	Antígeno prostático específico	es
dc.subject	Neoplasias de la próstata	es
dc.subject	Análisis de regresión	es
dc.subject.mesh	Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy	es
dc.subject.mesh	Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies	es
dc.subject.mesh	Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Gene Frequency	es
dc.subject.mesh	Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans	es
dc.subject.mesh	Medical Subject Headings::Check Tags::Male	es
dc.subject.mesh	Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Neoplasm Grading	es
dc.subject.mesh	Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycosides::Nucleotides	es
dc.subject.mesh	Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide	es
dc.subject.mesh	Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Serine Endopeptidases::Kallikreins::Prostate-Specific Antigen	es
dc.subject.mesh	Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms	es
dc.subject.mesh	Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysis	es
dc.title	Prognostic role of genetic biomarkers in clinical progression of prostate cancer.	es
dc.type	research article
dc.type.hasVersion	VoR
dspace.entity.type	Publication